07:40 AM EDT, 09/17/2025 (MT Newswires) -- X4 Pharmaceuticals ( XFOR ) said Wednesday it plans to undergo a strategic restructuring and reduce its workforce by half, which it expects to result in annualized cost savings of around $13 million.

The move aims to align X4's focus on successfully completing the phase 3 trial for mavorixafor in patients with moderate and severe chronic neutropenia, the company said.

X4 President John Volpone has been appointed as chief operating officer in addition to his current role. He succeeds Mary DiBiase, who will be exiting the company along with chief commercial officer Mark Baldry and chief legal and compliance officer Natasha Thoren, X4 said.

Executive Chairman Adam Craig will oversee clinical development, while chief medical officer Christophe Arbet-Engels has resigned for personal reasons but will be available to assist with transition activities, the company said.

X4 shares were down 0.9% in premarket trading.